Company* (Country; Symbol) |
Company* (Country; Symbol) |
Type/Product Area |
Terms/Details (Date) |
| | |||
Accelrys Inc. (subsidiary of Pharmacopeia Inc.; PCOP) |
Confirmant Ltd.* (UK) |
Agreement to produce a database of highly annotated proteins |
Accelrys will license its GeneAtlas software product to Confirmant, which will use it to annotate the function of protein sequences contained within its Protein Atlas of the Human Genome (2/11) |
|
|||
AcroMetix Corp.* |
Nabi Biopharmaceuticals (NABI) |
Exclusive agreement to develop ViroSure quality-control products for infectious disease testing for clinical laboratories and blood screening organizations |
Nabi will develop and manufacture the products while AcroMetrix will focus on marketing and distribution (1/30) |
|
|||
Amedis Pharmaceuticals Ltd.* (UK) |
Argenta Discovery Ltd.* (UK) |
Collaboration to focus on the application of Amedis' artificial intelligence technology platform to further enhance Argenta's drug discovery processes |
Financial terms were not disclosed (1/14) |
|
|||
Amersham Biosciences |
Geneva Bioinformatics SA* (Switzerland) |
Collaboration to develop and distribute bioinformatics and training tools |
The agreement combines Amersham Biosciences' proteomics experience and GeneBio's experience in the bioinformatics field with the goal of bringing improved bioinformatics tools to market (1/8) |
|
|||
Amylin Pharmaceuticals Inc. (AMLN) |
Restoragen Inc.* |
Agreement for Amylin to acquire rights to a Phase II program using continuous infusion of glucagon-like peptide 1, targeted to treat congestive heart failure in patients ineligible for transplant |
Amylin also will acquire rights to various GLP-1-related patents; Amylin will pay Restoragen about $4M, as well as milestone payments and royalties on products that result (12/26) |
|
|||
Atugen AG* (Germany) |
Isis Pharmaceuticals Inc. (ISIS) |
Intellectual property license agreement for specific functional genomic patents from Isis |
Atugen gains rights to practice Isis' antisense-based functional genomics technology, and to use antisense for discovery and validation of targets and for small-molecule drug discovery research in its programs (1/16) |
|
|||
Atugen AG* (Germany) |
MetaGen Pharmaceuticals GmbH* (Germany) |
Agreement to evaluate Atugen's target validation technology in the research and development of MetaGen's cancer drug targets |
Atugen will select and screen antisense oligonucleotides and optimize cellular delivery (2/19**) |
|
|
||
AxCell Biosciences (unit of Cytogen Corp.; CYTO) |
Celgene Corp. (CELG) |
Research collaboration to study the role of ubiquitin ligases in cancer and inflammation |
Both companies will investigate specific ubiquitin ligases as potential therapeutic targets for the treatment of cancer and inflammation based on their combined technologies and expertise (1/21) |
|
|
||
BioFocus plc |
Amgen Inc. (AMGN) |
Agreement in which BioFocus will provide Amgen with assay development, high-throughput screening, chemistry and molecular informatics |
BioFocus will receive research fees and milestone payments (1/13) |
|
|||
Biogen Inc. (BGEN) |
IDEC Pharmaceuticals Corp. (IDPH) |
Agreement in which IDEC will co-develop three oncology therapeutics |
The deal involves an anti-lymphotoxin beta receptor monoclonal antibody that is preclinical, an early development anti-CRIPTO monoclonal antibody and an interferon beta gene delivery product for glioma that is in Phase I; IDEC will fund development for four years and made a $1.5M licensing payment (1/31) |
|
|||
BioMimetic Pharmaceuticals Inc.* |
ZymoGenetics Inc. (ZGEN) |
Licensing agreement for the development and commercialization of ZymoGenetics' recombinant human platelet-derived growth factor for bone diseases and defects |
BioMimetic will study the PDGF for regeneration and repair of hard tissues for defects and diseases of the entire skeletal system (2/6) |
|
|
||
Biosite Inc. (BSTE) |
Ciphergen Biosystems Inc. (CIPH) |
Collaboration in cardiovascular and other diseases primarily to facilitate the discovery of antibody and protein target components that can be applied to either company's testing platform for diagnostic assays |
Biosite will provide clinical samples to address specific clinical questions (2/11) |
|
|||
BioStratum Inc.* |
DakoCytomation A/S* (Denmark) |
Agreement granting Dako-Cytomation a license to develop and commercialize diagnostic applications of the monoclonal antibody MetaStain, which has shown the potential to identify invasive epithelial cancers |
The license covers U.S. and foreign patents and patent applications, as well as the hybridoma that produces the antibody (2/18) |
|
|||
CallistoGen AG* (Germany) |
The Genetics Co. Inc.* (Switzerland) |
Agreement in which The Genetics Co. acquired Callis-toGen's portfolio of small-molecule candidates against Alzheimer's disease and its lead-generation platform |
The Genetics Co. also will gain access to a number of customers (1/22) |
|
|||
Cephalon Inc. (CEPH) |
MDS Proteomics Inc. (NYSE:MDZ) |
Five-year agreement to speed up the development of Cephalon's compounds and to expand the indications for them |
As part of the agreement, Cephalon bought a $30M convertible note due in 2010, convertible into stock of MDS Proteomics at $22 per share; Cephalon wants expanded indications for its approved drugs Provigil, Actiq and Gabitril (1/7) |
|
|
||
Columbia Laboratories Inc. (AMEX:COB) |
Ardana Bioscience Ltd.* (Scotland) |
Development and license agreement for Columbia's Chronodyne terbutaline vaginal gel product in development to treat infertility, dysmenorrhea and endometriosis |
Columbia received a $250,000 up-front payment, and would receive an additional $250,000 upon successful completion of a Phase II trial; if approved, Columbia would retain North American marketing rights, while Ardana would gain European rights; the parties would share equally in proceeds from licensing and distribution of the product in the rest of the world (12/30) |
|
|||
Compugen Ltd. (Israel; CGEN) |
Diagnostic Products Corp. (NYSE:DP) |
License agreement to develop and commercialize diagnostic assays based on two prostate-specific proteins for the screening, detection and monitoring of prostate and other cancers |
Compugen will receive undisclosed milestone payments and royalties based on the commercialization of its intellectual property, including Diagnostic Products' sales of any immunoassay-based products (1/22) |
|
|||
Crucell NV (the Netherlands; CRXL) |
Centocor Inc. (unit of Johnson & Johnson) |
Licensing agreement allowing Centocor to evaluate the production of monoclonal antibodies using the PER.C6 human cell line |
Centocor also has an option for a nonexclusive worldwide commercial product license to manufacture one or more specified monoclonal antibody products using the cell line; Crucell will receive an up-front payment, annual maintenance fees and potential royalties (1/16) |
|
|||
Crucell NV (the Netherlands; CRXL) |
Targeted Genetics Corp. (TGEN) |
Nonexclusive license agreement, which will evaluate and use PER.C6 for research and development in the vaccine field |
Targeted Genetics also received an option for a nonexclusive license to commercialize the resulting vaccines (2/17) |
|
|||
CytRx Corp. (CYTR) |
PSMA Development Co. |
Option agreement for PSMA to license TranzFect, CytRx's vaccine adjuvant technology (joint venture between Progenics Pharmaceuticals Inc., PGNX; and Cytogen Corp., CYTO) |
It would use TranzFect in a prostate cancer vaccine (1/16) |
|
|||
DeCode genetics Inc. (Iceland; DCGN) |
Vertex Pharmaceuticals Inc. (VRTX) |
Agreement for DeCode to gather and analyze pharma-cogenomic data as part of clinical trials its subsidiary Encode conducts on Vertex development compounds |
The agreement covers a Phase IIa trial of Vertex's VX-148 treatment for psoriasis (1/31) |
|
|||
Discerna Ltd.* |
Randox Laboratories Ltd.* |
Agreement in which Discerna will generate antibodies to a target owned by Randox |
If successful, Randox will take a nonexclusive license to Discerna's ribosomal display technology for use in diagnostic applications (2/5**) |
|
|||
Durect Corp. (DRRX) |
Pain Therapeutics Inc. (PTIE) |
Agreement to develop longer-acting opioid drugs |
Pain Therapeutics will provide an up-front fee plus milestone payments and royalties, as well as funding for certain formulation activities; the companies initially will focus on OxyTrex (1/14) |
|
|
||
EGeen International Corp.* |
Prediction Sciences LLC* |
Agreement to collaborate on the study and discovery of genetic variants responsible for variable patient responses to paroxetine (Paxil) |
EGeen will receive milestone payments and royalties on future product sales (1/13) |
|
|||
EntreMed Inc. (ENMD) |
Celgene Corp. (CELG) |
Agreement giving Celgene all rights to EntreMed's thalidomide analogue program, including ENMD 0995 and ENMD 0997 |
Celgene will assume certain EntreMed license payment obligations and will have the option for one year to select one of three preclinical products to develop; EntreMed receives $10M up front and will issue $16.75M in convertible preferred stock and warrants to Celgene; the warrants may be exercised for up to 7M shares, which could add $10.5M to the deal (1/2) |
|
|||
Europroteome AG* (Germany) |
Transgene SA (France; TRGNY) |
Collaboration to apply Euro-Proteome's proteomics and bioinformatics technology to analyze blood samples from a Phase I trial studying the Ad-IFNg cancer immunotherapy product belonging to Transgene |
The collaboration is designed to locate blood-borne biomarkers that correlate with clinical outcome parameters such as response to therapy (2/19) |
|
|||
Euroscreen SA* (Belgium) |
ICOS Corp. (ICOS) |
Exclusive licensing agreement for ICOS patents relating to the human CCR5 receptor and its role in HIV infection |
The patents will be combined with Euroscreen's own CCR5 receptor patents, and Euroscreen will sublicense the resulting expanded portfolio to partners for commercialization (1/6) |
|
|||
Evolva A/S* (Denmark) |
DakoCytomation Norden A/S* (Denmark) |
Agreement to jointly pursue the application of DakoCyto-mation's MoFlo flow cytometry technology platform to Evolva's Watchmaker technology |
If successful, the collaboration will enhance the utility of Watchmaker in drug optimization and open up a new application for flow cytometry in the pharmaceutical industry (2/19) |
|
|||
Evotec OAI AG (Germany; Neuer Markt:EVT) |
Dynogen Pharmaceuticals Inc.* |
Three-year agreement under which Dynogen will use Evotec's chemistry and biology capabilities to identify neurological compounds to treat genitourinary and gastrointestinal disorders |
Evotec will provide assay development, development of focused libraries and biological screening, among other services (1/30) |
|
|
||
Evotec OAI AG (Germany; Neuer Markt:EVT) |
Euroscreen SA* (Belgium) |
Cross-licensing agreement for patents relating to Euroscreen's AequoScreen technology and Evotec's Vlip technology |
Evotec also will have access to Euroscreen's GPCR (G protein-coupled receptor) re-agents, including cell lines, membrane preparations and functional analyses using AequoScreen; Evotec also may develop aequorin assays to pursue its own research programs, while the agreement permits Euroscreen to use Vlip for its research and commercial applications as well (1/21) |
|
|||
Evotec OAI AG (Germany; Neuer Markt:EVT) |
KeyNeurotek AG* and the Institute of Medical Technology Magdeburg GmbH (Germany) |
Drug discovery agreement to identify small-molecule drug candidates to treat distinct central nervous system, auto-immune, allergic and dermatologic diseases |
Evotec will assist KeyNeurotek and IMTM in developing new lead structures to two targets (1/14) |
|
|||
Evotec OAI AG (Germany; Neuer Markt:EVT) |
Oxagen Ltd.* (UK) |
Alliance to identify chemical compounds interacting with one of Oxagen's lead drug targets |
Evotec will apply its drug discovery process to express the target of interest, develop Ca2+ flux assays, screen the target against its library of drug-like small-molecule compounds and provide pro-filing services (1/8) |
|
|||
Evotec OAI AG (Germany; Neuer Markt:EVT) |
Psychiatric Genomics Inc.* |
Agreement to work on small-molecule drugs to treat psychiatric diseases |
Financial details were not disclosed (1/30) |
|
|||
Genaissance Pharmaceuticals Inc. (GNSC) |
Millennium Pharmaceuticals Inc. (MLNM) |
Licensing agreement for HAP Technology to Millennium for use in Millennium's drug discovery and development programs |
Millennium will pay Genaissance license fees in the multiyear agreement; Genaissance will have certain rights to support Millennium's DNA biomarker and pharma-cogenomic efforts (1/7) |
|
|||
GeneProt Inc.* (Switzerland) |
Serono SA (Switzerland; NYSE:SRA) |
Agreement under which Serono will test a set of data-mined polypeptides and proteins discovered and synthesized chemically by GeneProt |
Serono has an option to obtain an exclusive license to any of the polypeptides and proteins supplied by GeneProt (1/21) |
|
|||
Genome BioSciences |
Chemicon International Inc.* |
Technology sublicensing agreement that gives Chemicon the right to implement Genome Bio- Sciences' Positive-Positive Selection technologies |
Chemicon will use the technology to create knockout and knock-in transgenic mice for internal noncommercial research purposes (1/2) |
|
|||
Genome Therapeutics Corp. (GENE) |
Amgen Inc. (AMGN) |
Agreement to identify and develop therapeutic agents for bone diseases, including osteoporosis |
Genome Therapeutics will receive from Amgen an up-front cash payment and sponsored research funding, as well as potential milestone payments (1/2) |
|
|||
Genome Therapeutics Inc. (GENE) |
MerLion Pharmaceuticals Pte. Ltd.* (Singapore) |
Agreement to leverage validated antibacterial drug targets against MerLion's natural product libraries to select compounds for clinical development |
The two firms will share costs of the early stage research; Genome Therapeutics will provide screening assays to MerLion on target proteins known to be essential for the survival of many common pathogens; MerLion will screen the targets against its natural product libraries to isolate and identify novel chemical entities with an inhibitory effect on the target proteins (1/28) |
|
|
||
Genomics Collaborative Inc.* |
Celera Diagnostics (joint venture between the Applied Biosystems Group, NYSE:ABI; and Celera Genomics Group, NYSE:CRA) |
Agreement to support Celera's efforts to identify genetic patterns associated with rheumatoid arthritis |
Genomics Collaborative will provide access to its DNA sample sets associated with RA, matched with unaffected control samples; Celera Diagnostics plans to analyze the samples to identify genetic markers and disease; GCI will receive an up-front payment, as well as milestone payments on any products commercialized (1/16) |
|
|||
GPC Biotech AG (Germany; FSE:GPC) |
Ariad Pharmaceuticals Inc. (ARIA) |
Nonexclusive agreement that allows GPC to use intellectual property from Ariad's Argent cell-signaling regulation technology in GPC's LeadCode drug discovery and Reverse Genomics platform |
Further details were not disclosed (2/4) |
|
|||
ID Biomedical Corp. (Canada; IDBE; TSE:IDB) |
Dynport Vaccine Co. LLC* (joint venture between DynCorp and Porton International Inc.; UK) |
Subcontract agreement to develop a second-generation subunit plague vaccine |
The subcontract provides ID Biomedical with about $6M to clone, express and produce a subunit recombinant plague vaccine antigen (1/15) |
|
|
|
|
Igeneon AG* (Austria) |
Immunicon Corp.* |
Collaboration aimed at the registration of Igeneon's cancer immunotherapies and to expand the indications for use of Immunicon's diagnostic tests |
Both companies are focused on cancers of the epithelial origin (2/18) |
|
|||
Inflazyme Pharmaceuticals Inc. (Canada; TSE:IZP) |
Helicon Therapeutics Inc.* |
Exercised option agreement for Helicon to license the IPL455,903 compound from Inflazyme |
Helicon will pay $250,000 for the compound and plans to develop it as a potential drug for memory disorders; Inflazyme may supply certain development resources to Helicon, at Helicon's cost; Inflazyme has the option to form a 50/50 joint venture with Helicon for further development and subsequent commercialization (1/23) |
|
|||
Ingenium Pharmaceuticals AG* (Germany) |
Incyte Genomics Inc. (INCY) |
License agreement for Incyte patents directed at animal genetic modification |
The license provides Ingenium increased freedom to market in the U.S. its INGENO-typing technology, a method for producing murine models with subtle gene alterations for use in drug discovery and development (1/21) |
|
|||
Ingenium Pharmaceuticals AG* (Germany) |
Sequenom Inc. (SQNM) |
Research agreement in which Ingenium will use its INGENO-typing platform technology to produce murine models with subtle gene alterations for Sequenom's internal drug discovery and development programs |
The models will contain modifications in select disease-related genes located through Sequenom's discovery genetics programs (2/10) |
|
|||
KuDOS Pharmaceuticals Ltd.* (UK) |
MerLion Pharmaceuticals Pte. Ltd.* (Singapore) |
Two-year discovery and pre-clinical research collaboration to bring together MerLion's library of natural product compounds and KuDOS' validated targets to select lead candidates in the area of HPV-induced cervical cancer |
MerLion will be responsible for identifying and characterizing active substances from its library against KuDOS assays, and KuDOS will then progress the compounds through initial pharmacological screening (1/27) |
|
|
||
Large Scale Biology Corp. (LSBC) |
Novozymes Biotech Inc.* |
Research collaboration to apply gene shuffling and molecular evolution technologies to genes of interest |
Novozymes will provide genes encoding proteins of commercial interest, and Large Scale Biology will apply techniques in an attempt to modify the properties of the protein products (1/30) |
|
|||
LION bioscience AG (Germany; LEON) |
Cellzome AG* (Germany) |
Three-year license agreement for LION's SRS integration technology |
The technology is designed to allow researchers to better retrieve and analyze data; financial terms were not disclosed (1/24) |
|
|||
MaxCyte Inc.* |
Northern Therapeutics Inc.* |
Collaboration and license agreement to develop multiple nonviral, gene-based products to treat pulmonary diseases using MaxCyte's cell-loading system |
The parties will work to develop gene-based therapeutics for specific indications that can be administered at a patient's bedside; MaxCyte will receive up-front and milestone payments and research and development funding, as well as royalties from resulting products (2/4) |
|
|
||
Medarex Inc. (MEDX) |
Ability Biomedical Corp.* |
Collaboration on the development of fully human antibody drugs to treat inflammation and auto-immune diseases |
The companies expect to share equally the cost and responsibility of the development and plan to jointly commercialize any antibody products (1/7) |
|
|||
Medarex Inc. (MEDX) |
DiaDexus Inc.* |
Collaboration for the research and development of fully human antibody therapeutics |
Medarex plans to use its UltiMAb Human Antibody Development System to generate antibodies to disease targets identified by DiaDexus; the companies plan to develop antibodies against lung cancer targets, sharing the cost of research, development and commercialization, as well as potential profits; DiaDexus also plans to use UltiMAb technology to generate antibodies to other therapeutic targets outside the collaboration, for which Medarex could receive license fees and milestone payments, as well as royalties (1/29) |
|
|||
MorphoSys AG (Germany; Neuer Markt:MOR) five years |
Lonza Biologics plc* (UK) |
Agreement for production and supply of clinical-grade antibody drugs derived from MorphoSys' HuCAL technology within the next |
The agreement regulates access to Lonza's process development and manufacturing capacity for MorphoSys' own and partnered therapeutic antibody projects (1/27) |
|
|||
Morphotek Inc.* |
Abgenix Inc. (ABGX) |
Research agreement for the use of Morphodoma technology for the development of high-titer cell lines for the manufacturing of one of Abgenix's fully human monoclonal antibody product candidates |
Abgenix plans to apply Morphotek's technology to help enhance titer yields for the manufacture of preclinical and clinical material; Morphotek will receive an up-front research payment and research milestones upon successful achievement of program goals; it also may receive commercial license and milestone payments, as well as royalties (1/7) |
|
|||
Morphotek Inc.* |
Centocor Inc. (unit of Johnson & Johnson) |
Collaboration to use Morphodoma technology belonging to Centocor to develop high-titer cell lines for the commercial manufacturing of an undisclosed therapeutic antibody |
Morphotek will receive an undisclosed up-front research payment and research milestones upon achievement of program goals (1/21) |
|
|||
Oxford BioMedica plc* (UK) |
Kiadis BV* (the Netherlands) |
Agreement to begin a program directed at wound healing |
Oxford will apply findings from its Focused Target Identification platform, which identified an enzyme key for blood vessel growth; Kiadis will apply its High Resolution Screening technology to identify molecules that interact with the enzymes (1/28) |
|
|
||
PanVera LLC (subsidiary of Vertex Pharmaceuticals Inc.; VRTX) |
Invitrogen Corp. (IVGN) |
Agreement in which Invitrogen is purchasing certain product lines and technology rights from PanVera, including its biochemical and cellular assay capabilities and its commercial portfolio of proprietary re-agents, probes and proteins |
Invitrogen agreed to pay $95M in cash for the product lines and technology rights (2/4) |
|
|||
Pharmacopeia Inc. (PCOP) |
Celgene Corp. (CELG) |
Agreement to work together to identify small-molecule lead compounds that could be developed to treat inflammation |
Pharmacopeia's small-molecule discovery technology will be used to identify leads against a target selected by Celgene; Pharmacopeia will receive an undisclosed amount of research funding and will be entitled to receive milestone and royalty payments (2/3) |
|
|||
Polygenetics Inc.* |
Boston Scientific Corp.* |
License agreement giving Boston Scientific the ability to use Polygenetics' porous polymer microsphere technology to develop new products in the embolotherapy field |
Boston Scientific obtains an exclusive worldwide license to develop and commercialize the products and Polygenetics receives licensing fees, potential milestone payments and royalties (2/3) |
|
|||
PPD Inc. (PPDI) |
BioDelivery Sciences International Inc. (BDSI) |
License agreement granting PPD the right to apply BDSI's bioral nanodelivery technology to two therapeutic products |
BioDelivery will receive an up-front license fee, milestone payments based on certain regulatory filings and approvals, and royalties on worldwide sales (1/7) |
|
|||
Protein Design Labs Inc. (PDLI) |
MedImmune Inc. (MEDI) |
Licensing agreement for MedImmune's antibody humanization patents for up to three humanized antibodies over five years |
PDL will receive an up-front fee; upon exercise of a license for a particular antibody, PDL would receive an additional license fee and royalties on potential net sales (1/7) |
|
|||
Regeneron Pharmaceuticals Inc. (REGN) |
Serono SA (Switzerland; NYSE:SRA) |
Agreement to use Regeneron's Velocigene technology platform to provide Serono with knockout and transgenic mammalian models of gene function |
Serono will pay Regeneron up to $3M annually for up to five years; Regeneron will use Velocigene to provide knockout and transgenic models for target genes to be specified by Serono (12/23) |
|
|||
SkyePharma plc (SKYE) |
Enzon Pharmaceuticals Inc. (ENZN) |
Agreement to develop up to three drugs and to transfer to Enzon the North American rights to SkyePharma's DepoCyt |
Enzon will receive $3.5M for giving Skye-Pharma access to its PEG modification technology; SkyePharma will receive a milestone payment for each product based on its technology that enters Phase II development; the companies will share research and development costs; also, Enzon will pay SkyePharma a $12M licensing fee for rights to DepoCyt (1/2) |
|
|||
Sunesis Pharmaceuticals Inc.* |
Biogen Inc. (BGEN) |
Agreement for Sunesis to use its Tethering technology to discover therapeutics for inflammatory and autoimmune diseases in a collaboration with Biogen |
The exclusive worldwide licensing agreement gives Biogen the right to develop, manufacture and commercialize compounds resulting from the collaboration; Biogen will pay an up-front technology access fee, make quarterly payments and make a minority equity investment and a loan over the first 30 months of the collaboration; Sunesis could receive $60M in pre- commercialization milestones per target, as well as significant royalty payments based on product sales (1/7) |
|
|||
Xenova Group plc (UK; XNVA; LSE:XEN) |
ImmuLogic Pharmaceutical Corp. Liquidating Trust* |
Agreement under which Xenova will buy out all remaining ImmuLogic rights to future milestone and royalty payments relating to two of Xenova's development-stage vaccine programs, TA-CD and TA-NIC |
ImmuLogic will receive $1M from Xenova in return for ImmuLogic's rights to future payments relating to the two vaccine programs; mutual releases from claims, proceedings and any other liabilities also were exchanged (1/15) |
| | |||
Notes: | |||
# This chart does not include agreements that involve agricultural product development. | |||
* Private companies are indicated with an asterisk. | |||
** Denotes the date the item ran in BioWorld International. | |||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
AMEX = American Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange | |||
To read more on related topics, click on one of the words below.